Since the beginning of company’s foundation, various research and development projects are being performed. Human cells’ responses in various environmental conditions or presence of new biomaterials are studied within different applicative projects. Nevertheless, within translational projects cell therapy products for treating patients are being developed.
Within the project, novel biomaterials for dental implants that prevent biofilm formation will be developed and tested in vitro and in vivo. Our role is cytotoxicity and functional testing using cell-based assays.
The project is based on the development of a biobased antiviral/antimicrobial coating platform for high traffic surfaces and textiles. Our role within the international consortium is cytotoxicity testing of developed coatings using human skin primary cell cultures.
Project duration: 1. 9. 2022 – 31. 8. 2026
FP7-HEALTH; COATIM (278425)
The aim of the project was the development of antibiofilm coatings for dental and orthopaedic implants as biofilm associated infections represent an increasing problem for healthcare. GaiaCell performed in vitro testing of new coatings.
Project duration: 1. 1. 2012 – 31. 12. 2026
FP7-HEALTH; GENODISC (201626)
Intervertebral disc degeneration causes back pain which affects the quality of life in a large part of the population and poses huge economic and social burdens. Our role within the project was to investigate possibilities for disc repair using cell therapy approach.
Project duration: 1. 3. 2008 – 28. 2. 2013
Selected National funding projects:
Ministry of Economic Development and Technology; ADIPOCELL
The aim of the Adipocell project is the development of a medical device for MSC isolation from adipose tissue that could be used in an operational theatre.
Project duration: 9. 7. 2020 – 31. 8. 2022
Slovenian Research Agency; THE ROLE AND APPLICATION OF IMMUNOMODULATORY MESENCHYMAL STEM CELLS IN COVID-19 (L3-3176)
Within this project, extensive characterisation of our therapeutic cells will be performed in terms of purity, safety, differentiation potential, proliferation, senescence, and potency. MSCs or their secretome will also be tested in combination with SARS-CoV-2 infected epithelial cultures. GaiaCell participates as a co-financer.
Project duration: 1. 10. 2023 – 30. 9. 2024
Slovenian Research Agency; DEVELOPMENT AND IMPLEMENTATION OF NOVEL APPROACHES TO SOLVE PURITY AND QUALITY CHALLENGES OF THERAPEUTIC VIRUSES (L4-3180)
The aim of the project is to improve current technologies for production, downstream purification, and analytical characterisation of viral vectors. GaiaCell participates as a co-financer.
Project duration: 1. 10. 2021 – 31. 12. 2024
Slovenian Research Agency; HUMAN STEM CELLS-ADVANCED CELL THERAPY I – III (P3-0371)
A research programme covering all aspects of stem cell research, from basic science to translation of therapy into clinics in collaboration with the Blood Transfusion Centre of Slovenia and the University Medical Centre Ljubljana.
